Vifor Intl Company Profile
What is the competitive landscape for VIFOR INTL
VIFOR INTL has one approved drug.
There are twelve US patents protecting VIFOR INTL drugs.
Summary for Vifor Intl
| US Patents: | 12 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Vifor Intl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vifor Intl | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | AP | RX | Yes | Yes | 10,793,596 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |
| Vifor Intl | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | AP | RX | Yes | Yes | 8,236,766 | ⤷ Start Trial | ⤷ Start Trial | |||
| Vifor Intl | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | AP | RX | Yes | Yes | 8,217,007 | ⤷ Start Trial | ⤷ Start Trial | |||
| Vifor Intl | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | AP | RX | Yes | Yes | 8,486,894 | ⤷ Start Trial | ⤷ Start Trial | |||
| Vifor Intl | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | AP | RX | Yes | Yes | 9,359,399 | ⤷ Start Trial | ⤷ Start Trial | |||
| Vifor Intl | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | AP | RX | Yes | Yes | 10,017,536 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Vifor Intl | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | AP | RX | Yes | Yes | 9,334,305 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Vifor Intl Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2510399 | ⤷ Start Trial |
| Russian Federation | 2500685 | ⤷ Start Trial |
| Brazil | PI0718651 | ⤷ Start Trial |
| South Korea | 101513842 | ⤷ Start Trial |
| South Korea | 20090085096 | ⤷ Start Trial |
| Israel | 197923 | ⤷ Start Trial |
| Denmark | 2064228 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vifor Intl Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2064228 | 821 | Finland | ⤷ Start Trial | |
| 2064228 | 301199 | Netherlands | ⤷ Start Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT |
| 2064228 | C02064228/01 | Switzerland | ⤷ Start Trial | FORMER OWNER: CARA THERAPEUTICS, INC., US |
| 2064228 | 43/2022 | Austria | ⤷ Start Trial | PRODUCT NAME: DIFELIKEFALIN ODER EIN STEREOISOMER, EINE MISCHUNG VON STEREOISOMEREN, EIN PHARMAZEUTISCH ANNEHMBARES SALZ, HYDRAT, SOLVAT, SAEURESALZHYDRAT, N-OXID, ODER EINE ISOMORPHE KRISTALLINE FORM DAVON; REGISTRATION NO/DATE: EU/1/22/1643 (MITTEILUNG) 20220427 |
| 2064228 | 122022000071 | Germany | ⤷ Start Trial | PRODUCT NAME: DIFELIKEFALIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH UNBEDENKLICHEN SALZES, HYDRATS, SOLVATS, ODER SAEURESALZHYDRATS; AUTHORISATION NO/DATE: EU/1/22/1643 20220425 |
| 2064228 | LUC00282 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: DIFELIKEFALIN IN ALL FORMS COVERED BY THE BASIC PATENT; AUTHORISATION NUMBER AND DATE: EU/1/22/1643 20220427 |
| 2064228 | PA2022522 | Lithuania | ⤷ Start Trial | PRODUCT NAME: DIFELIKEFALINAS, BET KOKIA FORMA, KURIAI TAIKOMA PAGRINDINIO PATENTO APSAUGA ; REGISTRATION NO/DATE: EU/1/22/1643 20220425 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
